Current Studies

Here is a list of some of our current studies. For additional studies, please visit RecruitMe.

 

  • Principal Investigator

    Jonathan E. Posner, MD
    The pediatric neuroimaging lab is currently conducting a brain imaging study to understand how emotion and emotion regulation in youths. This study is for children and adolescents (11-17 years old). Healthy or anxious youths are eligible. The goal of this study is to advance our understanding of how the brain processes emotion in youths, and then to find out why certain youths feel more anxious than others. This study includes a brain imaging session, a diagnostic interview, psychological and behavior assessments. This study does not provide treatment.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    For this study, eligible participants will be asked questions about their symptoms and complete a medical evaluation. You will receive a medication, and be monitored by medical professionals. You will also be asked to complete questionnaires. The purpose of this study is to assess to evaluate a medication for the treatment of OCD.
  • Principal Investigator

    Jonathan E. Posner, MD
    In this study, we are trying to learn more about how stimulant medication produces an improvement in emotional lability (frequent mood changes and excessive emotional reactions) in patients with Attention Deficit Hyperactivity Disorder (ADHD.) Although ADHD is primarily associated with inattention, hyperactivity, and impulsivity, emotional ability plays a crucial role in the disorder.
  • The Neurocognition of Language Laboratory is seeking children from 6 12 years of age to participate in a brain study of visual-sensory processing. We will use a technique called electroencephalography (EEG) to measure the brains electrical activity by placing small electrodes that rest on the scalp. EEG is pain-free, safe, and non- invasive. We are looking for children with autism spectrum disorder (ASD) who do not take psychiatric medications and neurotypical children without psychiatric diagnoses.

  • Principal Investigator

    Martin J. Lan, MD, PhD

    We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (MRI and PET scan). You will also have antidepressant treatment for free. We will then be able to see whether information on the brain scans connects with how people do on the medications. The medications are common, and are not experimental. You will be able to discuss the treatment with Dr. Lan before starting the study to make sure that it is the proper treatment for you.

  • Principal Investigator

    Martin J. Lan, MD, PhD
    We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will have genetic testing and three different brain scans (one MRI and two PET scans). You will also receive an experimental medication for your depression named N-acetyl cysteine (NAC). Please contact us if you are interested in participating.
  • Principal Investigator

    Yuval Neria, PhD
    Columbia University Medical Center is presently recruiting individuals who have experienced trauma to participate in an fMRI research study. For your participation, you will receive up to $270 and an opportunity to advance research in the area of trauma and PTSD. This study involves two visits.
  • Principal Investigator

    Franklin R. Schneier, MD
    We are currently enrolling individuals with social anxiety disorder to participate inthis study. The purpose of this study is to assess whether a brief computer-basedresearch treatment helps improve social anxiety symptoms. For eligibleparticipants, this study will involve a brief, novel research treatment for socialanxiety, delivered in 8 or 12 sessions over the course of 4 or 8 weeks.Participants will receive payment for completing study assessments. The studywill also assess the effect of research treatments on brain activity using a scancalled magnetic resonance imaging (MRI).
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting.
  • Principal Investigator

    Michael G. Wheaton, PhD
    The purpose of this study is to learn more about how individuals with anxiety respond to a stress reactivity task. This study may help us to better understand the brain basis of anxiety so that we can improve anxiety treatments. You will be asked to complete a stress reactivity task and questionnaires about your symptoms and health for compensation of up to $100.
  • Principal Investigator

    Patrick J. Brown, PhD
    The goal of this open-administration treatment study of escitalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of frailty in older adults with depressive symptoms. Patients with significant depressive symptoms and 1 or more symptoms of the frailty syndrome (exhaustion, decreased energy, weight loss, decreased grip strength, and slow/unsteady gait) will be evaluated and treated with approved antidepressant medication for 8 weeks to test whether antidepressant medication improves both the syndrome of frailty and depressive symptoms.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD

    The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither compound is currently FDA-approved for treating OCD.

  • Principal Investigator

    Joanna E. Steinglass, MD
    This NIMH-funded research study examines whether there are differences in the brain when people with eating disorders make decisions about food. We hope to understand the neurobiology of eating disorders so that we can improve treatment. Participation includes computer tasks, brain imaging (MRI), and a measure of eating behavior. Eligible individuals will receive inpatient or outpatient treatment at no cost.
  • Principal Investigator

    David J. Hellerstein, MD
    This is a pre-marketing (Phase 2A) multi-site study of an investigational drug, ganaxolone, as a potential treatment for non-psychotic post-partum depression. Eligible subjects who agree by signing informed consent will spend four days on the 5-South Research Unit (5-S) of the New York State Psychiatric Institute. For 60 hours they will have an tube in a vein into which randomly assigned intravenous ganaxolone or placebo will be infused. Mood and adverse events will be assessed throughout their 5-S stay and at weeks 1, 2, 3 and 4. The initial cohort of 10 patients have completed.
  • Principal Investigator

    Joanna E. Steinglass, MD
    A research study at the New York State Psychiatric Institute and Columbia University Medical Center is looking for healthy teens between the ages of 14 and 18 years to participate in a study about food. Come in to the lab three times over the course of two years and get up to $250 each time for your participation. For more information and to see if you are eligible, call the Columbia Center for Eating Disorders at 646 774 8066.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of major depression and why some people feel suicidal or may act on such thoughts. The investigators hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings to improve treatment and prevention. Individuals may qualify if they have depression with or without suicidal thoughts or any history of suicide attempts. Participation involves a detailed diagnostic set of interviews, brain imaging scans (MRI and PET) and neuropsychological tasks.
  • Principal Investigator

    Frances R. Levin, MD
    The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
  • Principal Investigator

    Jeffrey M. Miller, MD
    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.
  • Principal Investigator

    Jeffrey M. Miller, MD
    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.
  • Principal Investigator

    Jeffrey M. Miller, MD

    The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS. Previous studies using tDCS have shown that it is helpful in treating conditions like depression and chronic pain. tDCS is administered using two small electrodes that are applied to the scalp. A low current is applied to the electrodes using a battery-operated device.

  • Principal Investigator

    Michael F. Grunebaum, MD
    If you're experiencing an acute psychiatric emergency, please stop negotiating this website and call 911 or go to the nearest emergency room. This website is not designed to address an acute psychiatric emergency. Purpose: To find out whether intranasal ketamine, when added to standard antidepressant treatment, improves the outcome of treatment for people with depression and suicidal thinking. All patients in the study will receive standard treatment for depression. Some will receive intranasal ketamine and others will receive inactive placebo.
  • Principal Investigator

    Barbara H. Stanley, PhD

    This study conducts behavioral tasks to explore the biological causes of depression and suicidal behavior. We hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings so we can improve treatment and prevention. Participants can have depression with or without a suicidal thoughts or any history of suicide attempts. Participation involves clinical assessments, a week-long phone survey, a stress test and computer games.

  • Principal Investigator

    Jeremy Veenstra-Vanderweele, MD
    The Translational Medicine Program at the Center for Autism and the Developing Brain is recruiting individuals with autism from 5 17 years of age with an IQ over 70 to participate in our study called aV1ation. The purpose of this study is to test an investigational medicine that blocks a hormone receptor in the brain linked to the control of socialization, stress, anxiety and aggression. We want to see if this medicine is effective as a treatment to help improve social functioning in children with ASD.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD

    The Center for OCD and Related Disorders and the Institute of Genomic Medicine is conducting a study to look for genetic causes of OCD. Our goal is to look at the genes of individuals with OCD to see if we can identify what may have put those individuals at risk for OCD. Participants will receive a clinical evaluation at no cost, a blood draw (up to 2 tablespoons) and compensation for their time. Significant findings from these genetic tests will be reported back to participants (if they chose to be notified of results).

  • Principal Investigator

    Bret R. Rutherford, MD
    In this research study, you will be fitted with hearing aids that may be fully tuned to improve your hearing (full dose) or may be only partially tuned and not likely to substantially improve your hearing (low dose). You will receive a free hearing aid that will be at full dose at the end of the 12 week study. You may also choose to receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or duloxetine (Cymbalta).
  • Principal Investigator

    Eleanor McGlinchey, PhD
    We are conducting research to compare different ways of improving sleep and mood in teens. Treatment involves Behavioral Sleep Therapy and Interpersonal Psychotherapy for Adolescents targeting: depression trouble falling and staying asleep not feeling rested on waking feeling sleepy during the dayStudy Procedures: ~ A free, thorough diagnostic evaluation ~ A full course of therapy (8-20 sessions) at no cost ~ Saliva collection and sleep monitoring before and after treatment ~ Study evaluations and treatment will be provided at no cost to you.